NeuroSense Therapeutics Ltd.

NRSN Nasdaq SEC CIK 1875091
Follow NeuroSense Therapeutics Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2023 USD · IFRS
Net income −$11.3M +8.6% vs prior year
EPS, diluted −$0.83 +22.4% vs prior year
Operating cash flow −$8.5M −11.4% vs prior year
Operating income −$13.3M +1.8% vs prior year
Net income by fiscal year
−$1.2M
−$2.8M
−$4M
−$12.3M
−$11.3M
FY19 FY20 FY21 FY22 FY23

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income6 fiscal years
−$15M−$10M−$5M$0FY18FY19FY20FY21FY22FY23
Show the numbers
YearNet income
FY23−$11.3M
FY22−$12.3M
FY21−$4M
FY20−$2.8M
FY19−$1.2M
FY18-
Free cash flowOperating cash flow minus capital expenditure
−$10M−$7.5M−$5M−$2.5M$0FY18FY19FY20FY21FY22FY23
Show the numbers
YearFree cash flow
FY23−$8.5M
FY22−$7.7M
FY21−$1.6M
FY20−$704K
FY19−$589K
FY18-